Abstract
Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Current Vascular Pharmacology
Title: Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Volume: 6 Issue: 1
Author(s): Armando Rojas, Enrique Mercadal, Hector Figueroa and Miguel A. Morales
Affiliation:
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Abstract: Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Export Options
About this article
Cite this article as:
Rojas Armando, Mercadal Enrique, Figueroa Hector and Morales A. Miguel, Advanced Glycation and ROS: A Link between Diabetes and Heart Failure, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331312
DOI https://dx.doi.org/10.2174/157016108783331312 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?
Current Vascular Pharmacology Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry The Role of Prostaglandins in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Osmoadaptation of Mammalian Cells - An Orchestrated Network of Protective Genes
Current Genomics A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions
Current Pharmaceutical Design Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Editorial (Thematic Issue: Drug Design and Discovery Targeting Ion Channels)
Current Topics in Medicinal Chemistry Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design